Drugs Generic: Mylan Inc (NASDAQ:MYL), Zoetis Inc (NYSE:ZTS), Actavis plc (NYSE:ACT), Mallinckrodt PLC (NYSE:MNK)



Trade-Ideas LLC identified Mylan Inc (NASDAQ:MYL) as an unusual social activity candidate. MYL has more that 20x the normal benchmarked social activity for this time of the day compared to its average of 2.07 mentions/day. Mylan Inc (NASDAQ:MYL) stock performance was 1.17% in last session and finished the day at $52.63. Traded volume was 7.39million shares in the last session and the average volume of the stock remained 4.11million shares. The beta of the stock remained 1.00. Mylan Inc (NASDAQ:MYL) insider ownership is 0.60%.

Veterinary drug manufacturer Zoetis Inc. (NYSE:ZTS), which manufactures animal vaccines in Lincoln, announced in February it is partnering with Iowa State University to identify and test a vaccine. Zoetis Inc (NYSE:ZTS) rose 0.58 percent to $29.42 Friday on volume of 4.02million shares. The intra-day range of the stock was $29.23 to $29.82. Zoetis Inc (NYSE:ZTS) has a market capitalization of $14.71 billion.

Generic drug makers, Actavis plc (NYSE:ACT) and Mylan Inc. ( MYL ), are gearing up to launch their generic versions of Pfizer’s ( PFE ) Celebrex (celecoxib). Actavis plc (NYSE:ACT)’s stock on Mar 14, 2014 reported a increase of 1.72% to the closing price of $214.52. Its fifty two weeks range is $89.20-$230.77. The total market capitalization recorded $28.42billion. The overall volume in the last trading session was 2.17million shares. In its share capital, ACT has 132.50million outstanding shares.

Depomed Inc (NASDAQ:DEPO) is a specialty pharmaceutical company. The company licenses out its drug technologies and collects royalties on the same. The company is now set to receive $10 million after the U.S. Food and Drug Administration approved a drug developed by Mallinckrodt PLC (NYSE:MNK) using its technology. The drug is target at pain treatment. On Friday, shares of Mallinckrodt PLC (NYSE:MNK) advanced 4.35% to close the day at $70.01. Company return on investment (ROI) is 3.50% and its monthly performance is recorded as 5.71%. Mallinckrodt PLC (NYSE:MNK) quarterly revenue growth is 35.02%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone